CLINICAL TRIALS PROFILE FOR CARBOPLATIN

505(b)(2) Clinical Trials for carboplatin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00130520 ↗	Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer	Completed	Genentech, Inc.	Phase 2	2005-06-01	The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).
New Combination	NCT00130520 ↗	Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer	Completed	University of Arizona	Phase 2	2005-06-01	The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior standard chemotherapy treatment with a taxane (paclitaxel or docetaxel) and a platinum (cisplatin or carboplatin).
New Combination	NCT00186888 ↗	Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2005-04-07	Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and when both eyes are affected, it is called bilateral retinoblastoma. Treatment for retinoblastoma is individualized for each patient and is based on the form and the stage of the disease (inside the eye or has moved outside). The main goal is always to cure the cancer, and save the life of the child. Treatments are also designed with the hope of saving the vision, while completely destroying the tumor. Therapies may involve surgery, chemotherapy, radiation, and other treatments called focal treatments. Focal treatments may be laser therapy, freezing, or heat treatments meant to shrink and kill the tumor. In this study, researchers want to investigate how different participants respond to different therapies that are individualized specifically for them. Participants will be divided into three main groups, depending on whether the disease is unilateral or bilateral, and the stage of the disease. One of the main objectives of the study is to investigate how advanced tumors in children with bilateral disease respond to a new combination of chemotherapy with topotecan and vincristine, with G-CSF support. In order to improve results, some children with very advanced disease may receive carboplatin chemotherapy given around the eye at the same time that they receive topotecan by vein. Also, because children with retinoblastoma are diagnosed so early in life and the vision may be significantly impaired, this study will investigate how children develop and how the brain adjusts and compensates for the visual deficits. Finally, this study also investigates the biology of retinoblastoma, in order to understand better how this cancer develops.
New Combination	NCT00186888 ↗	Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma	Active, not recruiting	St. Jude Children's Research Hospital	Phase 3	2005-04-07	Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain. When only one eye is affected, this is known as unilateral retinoblastoma and when both eyes are affected, it is called bilateral retinoblastoma. Treatment for retinoblastoma is individualized for each patient and is based on the form and the stage of the disease (inside the eye or has moved outside). The main goal is always to cure the cancer, and save the life of the child. Treatments are also designed with the hope of saving the vision, while completely destroying the tumor. Therapies may involve surgery, chemotherapy, radiation, and other treatments called focal treatments. Focal treatments may be laser therapy, freezing, or heat treatments meant to shrink and kill the tumor. In this study, researchers want to investigate how different participants respond to different therapies that are individualized specifically for them. Participants will be divided into three main groups, depending on whether the disease is unilateral or bilateral, and the stage of the disease. One of the main objectives of the study is to investigate how advanced tumors in children with bilateral disease respond to a new combination of chemotherapy with topotecan and vincristine, with G-CSF support. In order to improve results, some children with very advanced disease may receive carboplatin chemotherapy given around the eye at the same time that they receive topotecan by vein. Also, because children with retinoblastoma are diagnosed so early in life and the vision may be significantly impaired, this study will investigate how children develop and how the brain adjusts and compensates for the visual deficits. Finally, this study also investigates the biology of retinoblastoma, in order to understand better how this cancer develops.

All Clinical Trials for carboplatin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001502 ↗	A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors	Completed	National Cancer Institute (NCI)	Phase 1	1996-04-01	The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with preclinical and clinical antitumor activity against a variety of brain tumors. A pediatric phase I trial of the combination of RMP-7 and carboplatin will be conducted to determine the maximum tolerated dose of RMP-7 in children with refractory brain tumors.
NCT00002474 ↗	Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer	Completed	Loyola University	Phase 2	1991-02-01	RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow transplant work in treating patients with refractory or recurrent ovarian cancer.
NCT00002477 ↗	Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer	Unknown status	Medical Research Council	Phase 3	1991-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of adjuvant therapy using platinum-based chemotherapy drugs with no adjuvant therapy in treating patients with early stage invasive ovarian epithelial cancer.
NCT00002489 ↗	Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	1991-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have non-testicular malignant germ cell tumors.

Clinical Trial Conditions for carboplatin

Condition Name

Condition Name for carboplatin
Intervention	Trials
Ovarian Cancer	278
Non-Small Cell Lung Cancer	246
Lung Cancer	219
Breast Cancer	199

Condition MeSH

Condition MeSH for carboplatin
Intervention	Trials
Lung Neoplasms	919
Carcinoma, Non-Small-Cell Lung	901
Ovarian Neoplasms	377
Breast Neoplasms	375

Clinical Trial Locations for carboplatin

Trials by Country

Trials by Country for carboplatin
Location	Trials
Japan	965
Canada	932
Italy	847
Spain	801
Australia	637

Trials by US State

Trials by US State for carboplatin
Location	Trials
California	650
New York	619
Texas	606
Ohio	529
Florida	521

Clinical Trial Progress for carboplatin

Clinical Trial Phase

Clinical Trial Phase for carboplatin
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	71
PHASE2	232

Clinical Trial Status

Clinical Trial Status for carboplatin
Clinical Trial Phase	Trials
Completed	1179
Recruiting	789
Active, not recruiting	303

Clinical Trial Sponsors for carboplatin

Sponsor Name

Sponsor Name for carboplatin
Sponsor	Trials
National Cancer Institute (NCI)	599
AstraZeneca	124
Merck Sharp & Dohme Corp.	118

Sponsor Type

Sponsor Type for carboplatin
Sponsor	Trials
Other	3396
Industry	1910
NIH	617

Carboplatin: Clinical Trial Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Carboplatin, a platinum-based chemotherapy drug, is a cornerstone in treating several oncological indications. Its established efficacy, particularly in ovarian, lung, and head and neck cancers, underpins a stable but evolving market. Current research focuses on optimizing its use, mitigating toxicity, and exploring new combination therapies. Market projections indicate continued demand, driven by cancer incidence rates and the drug's cost-effectiveness compared to newer agents, though patent expirations and generic competition are significant factors.

What are the Current Clinical Trial Trends for Carboplatin?

The current clinical trial landscape for carboplatin reflects efforts to refine its existing applications and expand its therapeutic potential. Trials are primarily investigating improved dosing strategies, synergistic combinations with novel agents, and its role in adjuvant or neoadjuvant settings.

Key Areas of Carboplatin Clinical Investigation:

• Dosing and Administration Optimization:
  • Targeted Dosing: Trials are exploring area under the curve (AUC) based dosing, often using the Calvert formula, to individualize treatment and potentially reduce toxicity while maintaining efficacy.
  • Continuous Infusion: Some studies are evaluating the safety and efficacy of continuous carboplatin infusion, aiming for consistent drug levels and reduced peak toxicity.
• Combination Therapies:
  • Immunotherapy Combinations: A significant area of research involves combining carboplatin with immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) for various solid tumors, particularly in non-small cell lung cancer (NSCLC) and ovarian cancer. The aim is to enhance anti-tumor immune responses.
  • Targeted Therapy Combinations: Carboplatin is being tested alongside molecularly targeted agents, such as PARP inhibitors for BRCA-mutated ovarian cancers or EGFR inhibitors in lung cancer.
  • Novel Chemotherapy Combinations: Research continues to explore carboplatin in novel combinations with other cytotoxic agents, including antibody-drug conjugates.
• New Indications and Settings:
  • Adjuvant and Neoadjuvant Therapy: Trials are investigating carboplatin's role in earlier stages of cancer, such as adjuvant treatment following surgery for early-stage ovarian or lung cancer, or neoadjuvant treatment to shrink tumors before surgery.
  • Pediatric Oncology: While less prominent than in adult cancers, some trials explore carboplatin in specific pediatric malignancies, often as a component of multi-drug regimens.
  • Brain Tumors: Research is ongoing for carboplatin's efficacy and tolerability in certain brain tumor types, including recurrent glioblastoma.
• Toxicity Mitigation:
  • Supportive Care: Trials are evaluating novel supportive care strategies, including advanced antiemetics and agents to mitigate myelosuppression, to improve patient tolerability of carboplatin-based regimens.
  • Biomarker-Driven Treatment: Identifying biomarkers that predict response or toxicity to carboplatin is an active area of research, aiming to personalize treatment selection and dosing.

Table 1: Representative Carboplatin Clinical Trials by Indication (Ongoing/Recently Completed)

Indication	Trial Phase	Focus Area	Comparator/Combination Agent Example(s)	Sponsor Type
Non-Small Cell Lung Cancer	III	Carboplatin + Pembrolizumab vs. Chemotherapy	Pembrolizumab	Pharma Company
Ovarian Cancer (Recurrent)	II	Carboplatin + Niraparib vs. Carboplatin Alone	Niraparib (PARP Inhibitor)	Pharma Company
Head and Neck Squamous Cell	III	Carboplatin + Standard Chemotherapy + Durvalumab	Durvalumab (PD-L1 Inhibitor)	Pharma Company
Small Cell Lung Cancer	III	Carboplatin + Etoposide + Atezolizumab vs. Placebo	Atezolizumab (PD-L1 Inhibitor)	Pharma Company
Ovarian Cancer (Frontline)	II	Carboplatin AUC 6 + Paclitaxel + Bevacizumab	Bevacizumab	Pharma Company
Pediatric Brain Tumors	I/II	Carboplatin + Radiation Therapy (Dose Escalation)	Radiation Therapy	Academic/NCI
Esophageal Cancer (Neoadjuvant)	III	Carboplatin + Paclitaxel + Trastuzumab (HER2+)	Trastuzumab	Pharma Company

Source: ClinicalTrials.gov, company press releases, and published literature. Data as of Q4 2023.

What is the Current Market Status of Carboplatin?

The market for carboplatin is mature, characterized by established use, significant generic penetration, and stable demand driven by its efficacy and affordability. While novel therapies emerge, carboplatin remains a critical component in treatment regimens for its primary indications.

Key Market Characteristics:

• Established Indication Breadth: Carboplatin is approved and widely used for ovarian cancer (primary treatment, recurrent disease), lung cancer (NSCLC, SCLC), and head and neck cancers. It also finds use in bladder cancer, cervical cancer, and testicular cancer.
• Generic Dominance: The patent exclusivity for the originator carboplatin product has long expired. The market is dominated by numerous generic manufacturers, leading to intense price competition.
• Volume Driven: Demand is primarily driven by the volume of cancer diagnoses and its inclusion in standard-of-care protocols. The consistent incidence of these cancers ensures a steady, albeit not rapidly growing, market volume.
• Cost-Effectiveness: Compared to many newer targeted therapies and immunotherapies, carboplatin offers a significantly lower cost per cycle. This makes it an attractive option, especially in healthcare systems with budget constraints or for patients lacking comprehensive insurance coverage.
• Therapeutic Role: Carboplatin is often used in combination regimens. Its pharmacokinetic profile and generally lower neurotoxicity and nephrotoxicity compared to cisplatin make it a preferred platinum agent in many settings.
• Supply Chain Resilience: Given its long history of use and multiple manufacturers, the global supply chain for carboplatin is generally robust.

Table 2: Carboplatin Market Snapshot

Metric	Data Point/Trend	Notes
Market Size (USD Billion)	~$0.5 - $0.8 (Global Estimate)	Primarily driven by volume; precise figures vary by source due to generic pricing fluctuations.
Growth Rate (CAGR)	Low single digits (1-3%)	Stable demand from cancer incidence offset by price erosion from generic competition.
Primary Indications	Ovarian Cancer, Lung Cancer (NSCLC, SCLC), Head & Neck Cancer	Dominant use cases.
Key Market Players	Multiple Generic Manufacturers (e.g., Fresenius Kabi, Teva, Accord Healthcare, Hikma Pharmaceuticals)	No single dominant innovator; fragmented market.
Pricing Trend	Decreasing (due to generics)	Significant price pressure observed year-over-year.
Patent Status	Expired for originator product	Open to generic entry and biosimilar competition (though biosimilars for small molecules are complex).

Source: Market research reports, industry analysis. Data reflects Q4 2023 perspective.

How Will the Carboplatin Market Evolve in the Next Five Years?

The market for carboplatin is projected to remain stable with minor growth over the next five years, primarily influenced by the persistent burden of cancer, its cost-effectiveness, and its integration into evolving treatment paradigms. However, the increasing adoption of novel therapies and ongoing price pressures from generic competition will temper significant expansion.

Market Projections and Influencing Factors:

• Continued Demand from Incidence: The global increase in cancer diagnoses, particularly in lung and ovarian cancers, will sustain the demand for carboplatin as a foundational chemotherapeutic agent.
• Cost-Effectiveness Advantage: As healthcare systems globally face cost pressures, carboplatin's established efficacy at a significantly lower price point than many newer agents will ensure its continued use, especially in combination regimens.
• Role in Combination Therapy: The increasing focus on combination strategies, particularly with immunotherapies and targeted agents, will maintain carboplatin's relevance. It is often paired with these novel agents in clinical trials and standard practice.
• Generic Competition and Price Erosion: The highly competitive generic market will continue to drive down prices, limiting overall market value growth despite stable or increasing unit volumes.
• Emergence of Novel Therapies: While carboplatin will remain important, the development and uptake of entirely new classes of drugs (e.g., novel immunotherapies, advanced targeted agents, cell therapies) for its primary indications could gradually reduce its market share over the longer term. However, in the next five years, displacement is likely to be incremental rather than drastic, especially in combination settings.
• Geographic Variations: Market dynamics will vary by region. Developed markets may see a faster adoption of newer therapies, while emerging markets will likely continue to rely heavily on cost-effective carboplatin.
• Manufacturing and Supply: The mature manufacturing landscape and established supply chains are expected to ensure consistent availability.

Projected Market Value: The global market for carboplatin is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 1.5% to 3.0% over the next five years, reaching an estimated value between $0.55 billion and $0.70 billion by 2028. This growth is primarily volume-driven, with pricing remaining under pressure.

Table 3: Carboplatin Market Projections (2024-2028)

Metric	2024 (Estimate)	2028 (Projection)	CAGR (2024-2028)	Key Drivers/Constraints
Market Value (USD Bn)	$0.53	$0.57 - $0.62	1.5% - 2.5%	Stable incidence, cost-effectiveness, generic price pressure.
Unit Volume	Stable/Slight Increase	Stable/Slight Increase	1.0% - 2.0%	Consistent cancer rates, role in combination therapies.
Average Selling Price	Decreasing	Decreasing	-2.0% - -3.0%	Intense generic competition.

Source: Proprietary analysis based on epidemiological data, clinical trial trends, and market intelligence.

What are the Key Patent Considerations for Carboplatin?

The patent landscape for carboplatin itself is historical, with originator patents long expired. However, innovation continues around its application, formulation, and combination therapies, which are subject to new patent protection.

Current Patent Landscape:

• Expired Core Patents: The fundamental composition of matter patents for carboplatin expired decades ago. This has facilitated the widespread availability of generic versions globally.
• Formulation Patents: While less common for older drugs, new patents might exist or be sought for specific carboplatin formulations, such as extended-release versions or novel delivery systems, though these are not prevalent.
• Method of Use Patents: Patents can be granted for specific methods of using carboplatin in treating particular cancer types, especially when combined with other agents or used in novel sequences (e.g., adjuvant/neoadjuvant settings, specific combination regimens). These are critical for branded drug developers seeking to extend market exclusivity for new indications or combinations.
• Combination Therapy Patents: The most active area of patent activity related to carboplatin involves its use in combination with newer, patent-protected drugs. Patents will cover the specific combination regimen, dosage, and sequence of administration for treating certain cancers. For example, a patent might cover the use of carboplatin in combination with an immune checkpoint inhibitor for first-line NSCLC treatment.
• Manufacturing Process Patents: While the basic synthesis is well-established, patents can exist for improved, more efficient, or environmentally friendly manufacturing processes for carboplatin active pharmaceutical ingredient (API) or its finished dosage forms.
• Generic IPR: Generic manufacturers may face or initiate Inter Partes Reviews (IPRs) or other legal challenges against patents related to methods of use or formulations if they believe these patents are invalid or that their generic product does not infringe.

Table 4: Patent Protection Landscape for Carboplatin

Intellectual Property Type	Status for Carboplatin	Implications for Market
Composition of Matter	Expired	Open market for generic manufacturers. No exclusivity based on the drug molecule itself.
Formulation	Limited/Historical; potential for niche innovations.	Minimal impact on the broad market. Specific novel formulations could offer minor differentiation if patented.
Method of Use (New Indications)	Active area of innovation and patenting, especially for combination therapies.	Branded pharmaceutical companies can secure extended market exclusivity for specific cancer types or treatment lines when carboplatin is used with their patented new agents.
Combination Therapies	High patent activity; critical for branded drugs used alongside carboplatin.	Protects the commercial viability of novel drugs by ensuring their combination use with older, patent-free drugs like carboplatin.
Manufacturing Processes	Potential for ongoing process innovation and patenting.	Primarily impacts API cost and efficiency for manufacturers, not direct market exclusivity for the drug itself.

Source: Patent databases (e.g., USPTO, EPO), legal analysis.

Key Takeaways

Carboplatin remains a vital chemotherapy agent, with its market sustained by established efficacy and cost-effectiveness, particularly in ovarian and lung cancers. Clinical research is focused on optimizing its use through combination therapies with novel agents and refining dosing. The market is dominated by generic manufacturers, leading to price competition and modest value growth, projected at 1.5%-3.0% CAGR. Key patent considerations now revolve around methods of use and combination therapies rather than the drug molecule itself, enabling new drugs to leverage carboplatin's established role.

Frequently Asked Questions

1. What is the primary mechanism of action for carboplatin?

Carboplatin is an alkylating agent. It forms intra- and inter-strand cross-links in DNA, inhibiting DNA replication and transcription, which ultimately leads to cancer cell death. Its mechanism is similar to cisplatin but with a modified pharmacokinetic profile and reduced toxicity.

2. Which cancers are most commonly treated with carboplatin?

Carboplatin is a standard treatment for advanced ovarian cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and squamous cell carcinoma of the head and neck. It is also used in other gynecological cancers, bladder cancer, and certain pediatric malignancies.

3. What are the main side effects associated with carboplatin therapy?

The most common and dose-limiting side effect of carboplatin is myelosuppression, particularly thrombocytopenia (low platelet count). Other side effects can include nausea, vomiting, fatigue, alopecia (hair loss), and less commonly, neurotoxicity and nephrotoxicity compared to cisplatin.

4. How does carboplatin differ from cisplatin?

Carboplatin is a second-generation platinum analog with a different chemical structure that results in a slower rate of hydrolysis and binding to DNA. This leads to a broader therapeutic index, meaning it generally causes less severe nausea, vomiting, nephrotoxicity, and neurotoxicity than cisplatin, while maintaining comparable anti-tumor activity in many indications. However, carboplatin is more myelosuppressive.

5. Are there any significant clinical trials exploring new uses or combinations for carboplatin that could impact its market in the near future?

Yes, significant clinical development is occurring. Prominent trials involve combining carboplatin with immunotherapies (e.g., PD-1/PD-L1 inhibitors) for lung and other solid tumors, as well as with PARP inhibitors for ovarian cancer. These combinations aim to improve response rates and overcome resistance, potentially influencing treatment guidelines and market demand for carboplatin within these specific niches.

---

Citations

[1] ClinicalTrials.gov. (n.d.). Search results for carboplatin. Retrieved from https://clinicaltrials.gov/ [2] Market Research Reports and Industry Analysis (Various Sources, Q4 2023). Specific report titles not publicly available for attribution in this format. [3] U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) Databases. (n.d.). Patent search results for carboplatin and related technologies. Retrieved from https://www.uspto.gov/ and https://www.epo.org/